Summary of clinical results

Tolerance and efficacy in monotherapy of CLEANANCE Cleansing gel
Tolerance and efficacy of CLEANANCE gel cleanser as monotherapy in adolescents and adults with oily, acne-prone skin, under dermatological and ophthalmological control.
Population
52 subjects aged 12 to 37 with oily skin and mild to moderate acne with a total of 10 to 30 acne lesions (at least 5 non-inflammatory and at least 5 inflammatory lesions) on the face
Application of CLEANANCE cleansing gel
2 applications per day on face, upper back and chest for 4 weeks
Evaluation criteria
- Lion count
- Skin gloss measurement (clinical score from 0 = non-shiny skin to 9 = very shiny)
- Evaluation of sebum levels (Sebum Lipid Index)
- Skin and eye tolerance
Results
- Highly significant decrease in the number of acne lesions as early as D15: -24% of retention lesions and -47% of inflammatory lesions (p<0.001, versus D1)

Change in number of acne lesions (non-inflammatory, inflammatory) over 4 weeks
** p= statistically Highly Significant (p<0,001, versus D1)
- Highly significant reduction in skin shine immediately after application: - 16% (p<0.001, versus D1)

Changes in skin gloss (clinical rating) over 4 weeks
** p= statistically Highly Significant (p<0,001, versus D1)
- Highly significant decrease in lipid levels from D15 measured by sebumetry: -27% (p<0.001, versus D1)

Evolution of lipid index (sebum meter) over 4 weeks
** p= statistically Highly Significant (p<0,001, versus D1)
- Excellent skin tolerance, including in subjects with sensitive skin
- Very good ocular tolerance, including in subjects wearing contact lenses or with sensitive eyes
Conclusion
CLEANANCE cleansing gel used twice daily demonstrated efficacy on oily acne-prone skin as early as 2 weeks, by significantly reducing the number of acne lesions and the quantity of sebum
Excellent skin tolerance and very good ocular tolerance
More summaries of clinical results
Want to read on?
This access is reserved for professionals, registered on Pierre Fabre For Med.
To access the full content, please register or log in if you already have an account.